519-30-2

Basic information

• Product Name: dimethazan
• Synonyms: dimethazan;3,7-Dihydro-1,3-dimethyl-7-(2-dimethylaminoethyl)-1H-purine-2,6-dione;7-[2-(Dimethylamino)ethyl]-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione;Elidin;7-(2-dimethylaminoethyl)-1,3-dimethyl-purine-2,6-dione;7-(2-dimethylaminoethyl)-1,3-dimethylpurine-2,6-dione;7-(2-dimethylaminoethyl)-1,3-dimethyl-xanthine
• CAS NO: 519-30-2
• Molecular Formula: C₁₁H₁₇N₅O₂
• Molecular Weight: 251.288
• EINECS: 208-266-1
• Mol File: 519-30-2.mol
• Article Data: 0

Chemical Properties

• Melting Point: 95°
• Boiling Point: 441.4°Cat760mmHg
• Flash Point: 220.8°C
• Appearance: /
• Density: 1.31g/cm³
• Vapor Pressure: 5.45E-08mmHg at 25°C
• Refractive Index: 1.627
• CAS DataBase Reference: dimethazan(CAS DataBase Reference)
• NIST Chemistry Reference: dimethazan(519-30-2)
• EPA Substance Registry System: dimethazan(519-30-2)

Safety Data

• RIDADR: 3249
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 519-30-2(Hazardous Substances Data)

Usage

General Description

Dimetazan is a synthetic chemical compound that belongs to the class of phenylpiperazine derivatives. It acts as a central nervous system stimulant and is commonly used as a psychostimulant agent. Dimetazan has been found to increase the levels of neurotransmitters such as dopamine and noradrenaline in the brain, leading to enhanced alertness, focus, and cognitive function. It has also been studied for its potential as a treatment for attention deficit hyperactivity disorder (ADHD) and narcolepsy. However, its use is associated with potential side effects such as increased heart rate, elevated blood pressure, and insomnia. Due to its pharmacological effects, dimetazan is classified as a controlled substance and is regulated in many countries.

InChI:InChI=1/C11H17N5O2/c1-13(2)5-6-16-7-12-9-8(16)10(17)15(4)11(18)14(9)3/h7H,5-6H2,1-4H3

Upstream product

• 58-55-9 theophylline 
• 107-99-3 2-(dimethylamino)ethyl chloride